SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing fully human, multi-targeted, high-potency immunoglobulins (IgGs) without human donors or convalescent plasma to treat and prevent immune and autoimmune disorders. Its lead asset, SAB-142, targets type 1 diabetes with a disease-modifying approach. Using advanced genetic engineering, the company developed Transchromosomic (Tc) Bovine, the only transgenic animal with a human artificial chromosome, enabling the DiversitAb system to produce diverse, high-potency, fully-human IgGs for various unmet medical needs. We show 17 historical shares outstanding datapoints in our coverage of SABS's shares outstanding history.
Understanding the changing numbers of SABS shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like SABS versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching SABS by allowing them to research SABS shares outstanding history
as well as any other stock in our coverage universe. |
Free SABS Email Alerts:
Video: Shares Outstanding Importance
